Pradžia › Gyslainės melanoma › Ohio
Gyslainės melanoma klinikiniai tyrimai Ohio
8 tyrimai dėl Gyslainės melanoma ieško dalyvių vietose Ohio.
Miestai Ohio
Oficialus tyrimo tekstas (anglų kalba)
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
- Cleveland Clinic, Cleveland
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-15 · NCT07804186Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
- The Ohio State University, Columbus
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-09 · NCT06070012Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- University of Cincinnati Cancer Center, Cincinnati
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-06-08 · NCT03947385ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run, Columbus
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-05-13 · NCT03686124Neoadjuvant Darovasertib in Primary Uveal Melanoma
- Cole Eye Institute-9500 Euclid Ave, Cleveland
- Ohio State Eye and Ear Institute, Columbus
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-05-06 · NCT07015190A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- The Ohio State University, Columbus
Renkami dalyviai2/3 fazė
Visi amžiai · Visoms lytims · Atnaujinta 2026-04-02 · NCT06581406Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
- The Ohio State University Wexner Medical Center, Columbus
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Visi amžiai · Visoms lytims · Atnaujinta 2026-03-09 · NCT04792463A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
- Case Comprehensive Cancer Center, Cleveland
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-09-23 · NCT06805825Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.